DPVIL 50MG TAB 10 S

About

DPVIL 50mg contains vildagliptin, an oral antidiabetic medication belonging to the class of dipeptidyl peptidase-4 (DPP-4) inhibitors. It works by selectively inhibiting the DPP-4 enzyme, which is responsible for the inactivation of incretin hormones, glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP). By preserving the active forms of these incretins, vildagliptin enhances their ability to stimulate insulin release from pancreatic beta cells and suppress glucagon secretion from alpha cells in a glucose-dependent manner.

This mechanism of action leads to improved glycemic control by lowering both fasting and postprandial blood glucose levels without directly causing hypoglycemia when used as monotherapy. Vildagliptin is indicated for the treatment of type 2 diabetes mellitus in adults, often as an adjunct to diet and exercise, or in combination with other antidiabetic agents when monotherapy is insufficient.

Uses

• Management of type 2 diabetes mellitus.
• Improvement of glycemic control in adults.
• Used as an adjunct to diet and exercise.
• As monotherapy or in combination therapy.

Directions For Use

Take this medication orally as directed by your physician, usually once or twice daily, with or without food.

Benefits

• Effectively lowers blood glucose levels.
• Improves both fasting and postprandial glucose.
• Low risk of hypoglycemia as monotherapy.
• Glucose-dependent mechanism of action.
• Generally well-tolerated.
• Can be used in various combination therapies.

Side Effects

• Nasopharyngitis
• Headache
• Dizziness
• Joint pain
• Peripheral edema
• Constipation
• Cough
• Hypoglycemia (when combined with sulfonylurea or insulin)
• Pancreatitis (rare)
• Abnormal liver function tests (rare)
• Skin reactions
• Fatigue

Safety Measures

• Alcohol - No specific contraindication with moderate alcohol consumption, but excessive intake should be discussed with a doctor as it can affect blood sugar levels.
• Pregnancy - Generally not recommended during pregnancy due to insufficient data. Consult a doctor; insulin is often preferred for glycemic control in pregnant women with diabetes.
• Breastfeeding - It is unknown if vildagliptin is excreted in human milk. Use with caution and under medical supervision, weighing potential risks to the infant against maternal benefits.
• Liver - Not recommended for patients with moderate to severe hepatic impairment. Liver function tests should be monitored before and during treatment.
• Kidney - Dose adjustment may be required for patients with moderate to severe renal impairment. Consult your physician for appropriate dosing.
• Lung - No specific contraindications related to lung conditions.

Disclaimer

MedEHub is committed to delivering reliable, expert-reviewd information to help consumers make informed health decisions. However, the content provided on this website is for informational purposes only and is not intended to replace professional medical advice, diagnosis or treatment.

Always consult your doctor for any medical concerns, and discuss your questions about health conditions or medications with a qualified healthcare professional. Do not ignore or delay seeking professional medical advice based on information found on Med E Hub.

Our goal is to complement, not replace, the essential doctor-patient relationship.